 | Up a level |
Journal Article
Dietrich, Sascha, Oles, Malgorzata, Lu, Junyan 
ORCID: 0000-0002-9211-0746, Sellner, Leopold ORCID: 0000-0002-7893-401X, Anders, Simon ORCID: 0000-0003-4868-1805, Velten, Britta, Wu, Bian, Huellein, Jennifer, Liberio, Michelle da Silva, Walther, Tatjana, Wagner, Lena, Rabe, Sophie, Ghidelli-Disse, Sonja, Bantscheff, Marcus, Oles, Andrzej K., Slabicki, Mikolaj, Mock, Andreas, Oakes, Christopher C., Wang, Shihui, Oppermann, Sina, Lukas, Marina, Kim, Vladislav, Sill, Martin ORCID: 0000-0001-7616-7665, Benner, Axel, Jauch, Anna, Sutton, Lesley Ann, Young, Emma, Rosenquist, Richard, Liu, Xiyang, Jethwa, Alexander ORCID: 0000-0003-3869-8662, Lee, Kwang Seok, Lewis, Joe, Putzker, Kerstin, Lutz, Christoph, Rossi, Davide, Mokhir, Andriy, Oellerich, Thomas, Zirlik, Katja, Herling, Marco, Nguyen-Khac, Florence ORCID: 0000-0003-3107-6668, Plass, Christoph, Andersson, Emma, Mustjoki, Satu ORCID: 0000-0002-0816-8241, von Kalle, Christof, Ho, Anthony D. ORCID: 0000-0002-1656-0833, Hensel, Manfred, Duerig, Jan, Ringshausen, Ingo ORCID: 0000-0002-7247-311X, Zapatka, Marc ORCID: 0000-0001-8287-5967, Huber, Wolfgang ORCID: 0000-0002-0474-2218 and Zenz, Thorsten
(2018).
Drug-perturbation-based stratification of blood cancer.
J. Clin. Invest., 128 (1).
S. 427 - 446.
ANN ARBOR:
AMER SOC CLINICAL INVESTIGATION INC.
ISSN 1558-8238
Baertsch, Marc-Andrea, Schlenzka, Jana, Mai, Elias K., Merz, Maximilian, Hillengass, Jens, Raab, Marc S., Hose, Dirk, Wuchter, Patrick, Ho, Anthony D. ORCID: 0000-0002-1656-0833, Jauch, Anna, Hielscher, Thomas, Kunz, Christina, Luntz, Steffen, Klein, Stefan, Schmidt-Wolf, Ingo G. H., Goerner, Martin, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Salwender, Hans ORCID: 0000-0001-7803-0814, Scheid, Christof, Nogai, Axel, Haenel, Mathias, Lindemann, Hans W., Martin, Hans, Noppeney, Richard, Weisel, Katja and Goldschmidt, Hartmut
(2016).
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
BMC Cancer, 16.
LONDON:
BMC.
ISSN 1471-2407